A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerX. Cynthia, Paula M. Fracasso|Breast Cancer Research and Treatment|2012Cited by 107
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesPaula M. Fracasso, Helen Piwnica‐Worms|Cancer Chemotherapy and Pharmacology|2010Cited by 69
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0